DNA and RNA on a blackboardWe’re going back to biotech school this week, learning the ins and outs of clinical trials with Adam Feuerstein; working on a de-extinction homework assignment; and sneaking off campus during the afternoon free session to check in on the Nobel Prizes.

Biotech School: how to spot hidden danger signs in clinical trial data

Biotech journalist Adam Feuerstein has made a name for himself exposing the occasionally shady antics of biotech companies, and in this recent article for TheStreet he gives a clinical trial masterclass. “Using Northwest Bio as an example, I’m going to teach you how to read clinical trial data to find red flags and bad stuff biotechs don’t want you to see,” he writes.

Should we bring extinct species back from the dead?

Current estimates suggest that between 30 and 159 species disappear from the Earth every day, which would put the planet in the midst of its sixth ever mass-extinction event. As a result, some researchers have begin to think seriously about the case for ‘de-extinction’: using genetic techniques to bring back the species we’ve lost.

Is science only for the rich?

“Around the world, poverty and social background remain huge barriers in scientific careers,” argue¬†Nature. And while few countries collect detailed data on socioeconomic status, according to a bit of digging by the prestigious journal, the available numbers suggest that that nations are wasting the talents of underprivileged youth.

When a Nobel Prize brings a shower of hype: the roller coaster ride of RNAi

The Nobel Prizes are just around the corner, and once again CRISPR is the hot biotech tip for a gong. The hype surrounding the winning discoveries is certainly extensive, but it is warranted? Meghana Keshavan of STATNews looks at the cautionary tale of RNA interference.

And one from us…

Color Genomics raises $45M in series B. With a little help from Bono

Please leave your very best U2/genomics puns in the comments section below!